Tauriga Sciences, Inc. to Develop Airport Version of its CBD Infused Chewing Gum
NEW YORK, N.Y., Apr 10, 2019 - (ACN Newswire) - via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it is developing a special miniaturized Airport version of its CBD Infused chewing gum (branded as: Tauri-Gum(TM)). The Company recently announced an increase in its Research & Development ("R & D") budget, aimed at continually enhancing its Tauri-Gum(TM) product line. Tauriga envisions this Airport version consisting of a miniaturized blister pack, containing three pieces of its CBD Infused gum (anticipated retail price of $6.99 per unit). The Company is in the process of miniaturizing the graphic design and label wording, to correlate with this newest proposed product version.
| Artist's Rendition of Tauri-Gum(TM) Airport Version |
The Company believes that the Airport market segment represents a potentially lucrative opportunity for the Company, because of the well-known benefits of chewing gum while flying on airplanes. The act of chewing gum (any type of gum) equalizes the air pressure in the middle ear, thereby helping to alleviate the intensity of headaches and ear related discomfort (often experienced by air travelers).
Tauriga's CEO, Mr. Seth M. Shaw, expressed, "The Company believes that an Airport version of Tauri-Gum(TM) has the potential to unlock a major future business opportunity. Chewing gums, of all type, sell extremely well at airports and this plays into one of the Company's strengths. Tauriga formulated Tauri-Gum(TM) in a manner that is fully compliant with the prevailing U.S. Federal laws and regulations that govern this sector. Therefore, the Company feels confident that it can proceed with this above-mentioned corporate initiative and legally sell its product(s) at U.S. based airports."
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or "CBD") infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum(TM). See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com.
In addition, on March 11, 2019, the Company announced the official launch of its E-Commerce site - as part of its Tauri-Gum(TM) commercialization strategy. This site can be accessed by visiting the following URL address: www.taurigum.com
Forward-Looking Statements This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management's beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as "may," "will," "expects," "anticipates," believes, "hopes," "believes," or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management's present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the "Risk Factors" section of Tauriga's Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Additional Disclaimer Specific to this Press Release: There can be no guaranty that the Company will ultimately be successful in developing this Tauri-Gum(TM) Airport version or bringing it to market.
Attachment - 100+ DPI Image for April 9, 2019 PR https://bit.ly/2UHfNbs
CONTACT INFORMATION: Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY 10022 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 www.tauriga.com
Source: Tauriga Sciences, Inc. Sectors: Food & Beverage, BioTech, Healthcare & Pharm, Cannabis
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding Nov 16, 2024 18:00 JST
| Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki Nov 15, 2024 18:58 JST
| Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) Nov 15, 2024 17:33 JST
| Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease Nov 15, 2024 14:31 JST
| Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism Nov 15, 2024 12:32 JST
| Fujitsu collaborates with global suppliers in decarbonization initiative to exchange product-level primary data on CO2 emissions Nov 15, 2024 10:13 JST
| TANAKA Successfully Develops the World's First[1] Manufacturing Technology for Platinum Materials with Nano-Sized Crystal Grains Nov 15, 2024 04:00 JST
| myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth Nov 14, 2024 20:00 JST
| ULVAC Launches Oil Rotary Vacuum Pump Gv135 Nov 14, 2024 10:00 JST
| MHI Publishes MHI REPORT 2024 Nov 13, 2024 16:52 JST
| SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization Nov 13, 2024 12:38 JST
| Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program Nov 13, 2024 12:05 JST
| NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science Nov 13, 2024 11:16 JST
| All-New Triton Wins Special Award at the RJC Car of the Year for 2025 Nov 12, 2024 22:09 JST
| Toyota: HySE to participate in the Dakar 2025 "Mission 1000 ACT2" with the HySE-X2, to tackle further technical challenges Nov 12, 2024 20:04 JST
| NEC participates in COP29 climate change conference Nov 12, 2024 19:25 JST
| JA Mitsui Leasing and Fujitsu collaborate on simulation-driven field trials to optimize commercial EV adoption and drive decarbonization Nov 12, 2024 13:57 JST
| Macnica publishes Integrated Report on the theme of 'An Introductory Guide to Macnica's Mechanism' Nov 12, 2024 13:00 JST
| Hitachi: Established the Open Source Program Office (OSPO) to Globally Lead the Strategic Utilization of OSS Nov 11, 2024 10:31 JST
| Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Nov 08, 2024 10:31 JST
|
More Latest Release >>
|